ALX Oncology Holdings Inc. (ALXO) Revenue History
Annual and quarterly revenue from 2018 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ALXO Revenue Growth
ALXO Revenue Analysis (2018–2024)
As of May 8, 2026, ALX Oncology Holdings Inc. (ALXO) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, ALXO's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $4.8 million in 2019.
When compared to Healthcare sector peers including FATE (-51.2% YoY), RCUS (+67.4% YoY), and AGEN (+10.4% YoY). Compare ALXO vs FATE →
ALXO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ALXOCurrent | $0 | - | - | - | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% |
ALXO Historical Revenue Data (2018–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $0 | - | $-142,467,000 | - |
| 2023 | $0 | - | $0 | - | $-170,278,000 | - |
| 2022 | $0 | - | $0 | - | $-127,436,000 | - |
| 2021 | $0 | -100.0% | $0 | - | $-83,555,000 | - |
| 2020 | $1.2M | -75.4% | $107K | 9.1% | $-43,663,000 | -3694.0% |
| 2019 | $4.8M | +132.0% | $436K | 9.1% | $-19,183,000 | -400.0% |
| 2018 | $2.1M | - | $187K | 9.0% | $-13,684,000 | -662.0% |
See ALXO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALXO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALXO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonALXO — Frequently Asked Questions
Quick answers to the most common questions about buying ALXO stock.
Is ALXO's revenue growth accelerating or slowing?
ALXO TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is ALXO's long-term revenue growth rate?
ALX Oncology Holdings Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is ALXO's revenue distributed by segment?
ALXO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2024 are available for download. Segment mix reveals concentration and diversification trends.